Hot AI Mandate: Newly Established Europe-based VC Interested in Longevity-related Digital Technologies

4 Jan

A newly established venture capital firm was founded in 2020 and is based in Europe. The firm is currently raising its first fund targeting €30M, and expects to close in mid to late 2021 and become fully operative. The firm is actively seeking investment opportunities and performing due diligence on companies they identify as a fit with the firm. The firm’s focus is in Seed to Series A financings and initial size of investment will be around €500K, and can invest up to €2.5M over the life of investment. While the firm is open to USA-based opportunities, the firm will focus on those based in Europe, Israel, and Spain where the firm is based.

The firm is exclusively interested in companies in the longevity space. In this regard, the firm is most interested in digital technologies including AI, robotics, data analytics, etc. Traditional therapeutics or devices do not fall within their investment priority, as the firm prefers to seek opportunities that leverage digital technologies to deliver novel therapeutic solutions (i.e. digital therapeutics). The firm is open to very early-stage, pre-revenue technologies and are open to university spin-offs/tech transfers.

The firm is backed by co-founders who have entrepreneurial backgrounds and can be a hands-on investor, assisting with company creation and other support as needed. When investing in companies that are not in geographical proximity to the firm, the firm prefers to co-invest alongside larger VC firms.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot Longevity Mandates: Europe-Based Venture Fund

4 Jan

The firm is a venture capital investment firm founded in 2018 and is based in Germany. The firm is actively seeking medtech investment opportunities from Seed to Series B financing rounds, though the firm’s sweet spot is leading Series A investments. Initial check sizes can largely vary; the firm can invest anywhere from €1-5M, and seeks to invest €5-8M over the life of investment. With the current fund, the firm manages 5 portfolio companies, and seeks to invest in ~12 companies, for which the firm estimates 2/3 will be Europe/Israel-based companies, and 1/3 will be USA-based companies. Currently, the firm is not evaluating opportunities outside of USA, Europe, and Israel.

The firm is focused on investing in innovative medical devices that address cardiovascular or neurovascular disease. The firm does not invest in other sectors such as therapeutics, diagnostics, or digital health. Within medical devices, the firm is open to both pre-clinical (prototype) and clinical technologies. The firm has primarily evaluated PMA devices but is open to 510k regulatory pathways. The firm may consider other types of devices on a highly selective basis, but even such opportunities must have some connection or relevance to cardiovascular disease.

The firm prefers to lead investment rounds and seek board representation, though the firm can also co-invest alongside syndicates. Through the firm’s relationship with a proprietary commercialization and distribution platform, the firm is uniquely positioned to create value for their portfolio companies in the European market. Through this sister company relationship, the firm has access to a wide network including over 200 European hospitals, clinical sites, physicians, KOLs, etc. and can provide strategic advice on market strategy (EU clinical trials, regulatory process, reimbursement).

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot Longevity Mandate: US-Based Multinational Company

4 Jan

The company, headquartered in California, is a multinational healthcare technology company which develops, manufactures, and sells solutions to support the vision of a fully autonomous pharmacy. The company is focused on transforming the pharmacy care delivery model and executing on the vision of the autonomous pharmacy by delivering automation, intelligence, and advanced services, powered by a single, cloud-based platform. The company offers medication management automation solutions and adherence tools which empower healthcare systems and pharmacies to focus on clinical care rather than administrative tasks. The company is looking for global strategic partnerships with companies from their formation to commercialization. The company considers a variety of engagement models including acquisitions, collaborations and strategic investments when partnering with companies aligned with the firm’s core business and new areas of strategic interest. The firm is looking for global strategic partnerships with companies from their formation to commercialization. The company considers a variety of engagement models including acquisitions, research collaborations and strategic investments when partnering with companies aligned with the firm’s core business and new areas of strategic interest.

The firm is looking for strategic partnerships with early-stage companies in the medical device and digital health sectors. The company is open to subsector and indication as it relates to the company’s core business interest. The firm is open to pre-prototype companies and will consider class 1 and 2 medical device technologies.

The firm is open to all types of management teams with technologies relating to their focus and who have an interest in a strategic partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot Longevity Mandate: Corporate Venture Arm of Senior Living Community

4 Jan

The firm is the corporate venture arm of a senior living communities with in multiple locations and a seniors members club . The firm invests strategically in companies that can enhance their services or the elderly population quality of life in general, including in healthcare. Within healthcare, the firm is willing to invest in digital health, medical devices and diagnostic/monitoring technologies, but will not invest in therapeutics. The firm generally invests in seed to series A, and will occasionally act as a company builder, co-founding a company around a promising technology. In an initial investment, the firm will generally invest no more than $.5M, but has the ability to invest in follow-on rounds. As a strategic investor, in addition to capital, the firm can employ their facilities for pilot programs, and will occasionally do so before investing. The firm is primarily interested in Israeli companies, but will invest globally.

The firm invests in multiple sectors related to the elderly population quality of life. These technologies can include medical devices, diagnostics and digital health technologies. Examples include chronic disease management software or monitoring devices.

The firm is a strategic and active investor, and will generally take a board seat after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot Investor Mandate: Western Europe Based Firm Invests Up to 5M EUR in Medical Device Companies, From Seed to Series B

30 Dec

The firm is a venture capital investment firm founded in 2018 and is based in Germany. The firm is actively seeking medtech investment opportunities from Seed to Series B financing rounds, though the firm’s sweet spot is leading Series A investments. Initial check sizes can largely vary; the firm can invest anywhere from €1-5M, and seeks to invest €5-8M over the life of investment. With the current fund, the firm manages 5 portfolio companies, and seeks to invest in ~12 companies, for which the firm estimates 2/3 will be Europe/Israel-based companies, and 1/3 will be USA-based companies. Currently, the firm is not evaluating opportunities outside of USA, Europe, and Israel.

The firm is focused on investing in innovative medical devices that address cardiovascular or neurovascular disease. The firm does not invest in other sectors such as therapeutics, diagnostics, or digital health. Within medical devices, the firm is open to both pre-clinical (prototype) and clinical technologies. The firm has primarily evaluated PMA devices but is open to 510k regulatory pathways. The firm may consider other types of devices on a highly selective basis, but even such opportunities must have some connection or relevance to cardiovascular disease.

The firm prefers to lead investment rounds and seek board representation, though the firm can also co-invest alongside syndicates. Through the firm’s relationship with a proprietary commercialization and distribution platform, the firm is uniquely positioned to create value for their portfolio companies in the European market. Through this sister company relationship, the firm has access to a wide network including over 200 European hospitals, clinical sites, physicians, KOLs, etc. and can provide strategic advice on market strategy (EU clinical trials, regulatory process, reimbursement).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Company Developing Digital and Device Solutions for Pharmacies Looking to Partner Strategically with Companies at Any Stage

30 Dec

The firm, headquartered in Mountain View, CA, is a multinational healthcare technology company which develops, manufactures, and sells solutions to support the vision of a fully autonomous pharmacy. The company is focused on transforming the pharmacy care delivery model and executing on the vision of the autonomous pharmacy by delivering automation, intelligence, and advanced services, powered by a single, cloud-based platform. The firm offers medication management automation solutions and adherence tools which empower healthcare systems and pharmacies to focus on clinical care rather than administrative tasks.

The firm is looking for global strategic partnerships with companies from their formation to commercialization. The company considers a variety of engagement models including acquisitions, collaborations and strategic investments when partnering with companies aligned with the company’s core business and new areas of strategic interest.
The firm is looking for global strategic partnerships with companies from their formation to commercialization. The company considers a variety of engagement models including acquisitions, research collaborations and strategic investments when partnering with companies aligned with the firm’s core business and new areas of strategic interest.

The firm is looking for strategic partnerships with early-stage companies in the medical device and digital health sectors. The company is open to subsector and indication as it relates to the company’s core business interest. The firm is open to pre-prototype companies and will consider class 1 and 2 medical device technologies.

The firm is open to all types of management teams with technologies relating to their focus and who have an interest in a strategic partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: International Corporation Manufacturing R&D Tools and Instrumentation Investing, Co-Developing or Acquiring Companies That Are a Strategic Fit

30 Dec

Founded in 1960 the company is an international corporation that manufactures research tools and scientific instrumentation. Within the life sciences, the firm’s main focus is on instrumentation for research, including spatial biology, -omics platforms, and single cell analysis. The company has multiple partnership models including: investing, co-development, and acquisition. The firm is willing to partner globally, and prefers companies that have a pilot proof-of-concept with a potential client and a plan for early revenue before partnering with them.

Within instrumentation, the company partners with companies that are a strategic fit for the firm. The areas of interest include: spatial biology, microfluidic devices, -omics platforms, single cell analysis, and analytics. The firm’s main focus is on tools that are primarily for research use only, but will consider clinical diagnostics as well, especially when they are platform technologies with applications for both research and the clinic.

The company has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →